3 not yet recruiting, 2 completed, 1 active not recruiting, 1 enrolling by invitation. 5 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Active not recruiting 1, Enrolling by invitation 1, Not yet recruiting 1 |
| Phase 1 | 2 | Not yet recruiting 1, Withdrawn 1 |
| Phase 3 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Lumos Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults LUM-201, Placebo, Semagludtide - Obesity & Overweight | Phase 2 | Not yet recruiting | Lumos Pharma | 202 | 2027-02-15 | 2026-08-10 |
| Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency LUM-201 - Growth Hormone Deficiency (GHD) | Phase 3 | Not yet recruiting | Lumos Pharma | 150 | 2027-02-01 | 2026-07-08 |
| Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer NLG802 (indoximod Prodrug), Temozolomide - Progressive Pediatric Brain Cancer | Phase 1 | Not yet recruiting | Lumos Pharma | 30 | 2026-10-08 | 2026-07-28 |
| Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency LUM-201, Matched Placebo (Capsules) - Growth Hormone Deficiency (GHD) | Phase 3 | Recruiting | Lumos Pharma | 150 | 2026-05-20 | 2026-10-19 |
| A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211) LUM-201 - Growth Hormone Deficiency | Phase 2 | Enrolling by invitation | Lumos Pharma | 60 | 2023-08-01 | 2024-02-15 |
| Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors Stereotactic Body Radiotherapy (SBRT), navoximod, NLG802 (indoximod Prodrug) - Advanced Solid Tumors | Phase 1 | Withdrawn | Luke, Jason, MD | 2022-10-01 | 2022-09-30 | |
| Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213) LUM-201 - Growth Hormone Deficiency | Phase 2 | Completed | Lumos Pharma | 15 | 2022-02-18 | 2026-05-15 |
| PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212) LUM-201 - Growth Hormone Deficiency | Phase 2 | Active not recruiting | Lumos Pharma | 24 | 2021-07-14 | 2023-10-04 |
| Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial) LUM-201, rhGH Norditropin® pen (34 µg/kg) - Growth Hormone Deficiency | Phase 2 | Completed | Lumos Pharma | 104 | 2020-12-31 | 2026-06-17 |
Dwarfism, Pituitary (6) · Obesity (1) · Overweight (1)
Capsules (1) · Radiosurgery (1) · Temozolomide (1) · navoximod (1)
United States (5) · Australia (3) · Chile (2) · New Zealand (2) · Poland (2) · Argentina (1) · India (1) · Israel (1) · Thailand (1) · Ukraine (1) · United Kingdom (1)